Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments during the current depressive episode, the percentage of patients with remission is low and the percentage with relapse is high. The efficacy and safety of esketamine nasal spray as compared with extended-release quetiapine augmentation therapy, both in combination with ongoing treatment with a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI), in patients with treatment-resistant depression are unknown. METHODS: In an open-label, single-blind (with raters unaware of group assignments), multicenter, phase 3b, randomized, active-controlled trial, we assigned patients, in a 1:1 ratio, to receive flexible doses (according to the summary of product characteristics) of esketamine nasal spray (esketamine group) or extended-release quetiapine (quetiapine group), both in combination with an SSRI or SNRI. The primary end point was remission, defined as a score of 10 or less on the Montgomery-Åsberg Depression Rating Scale (MADRS), at week 8 (scores range from 0 to 60, with higher scores indicating more severe depression). The key secondary end point was no relapse through week 32 after remission at week 8. All patients were included in the analysis; patients who discontinued the trial treatment were considered as having had an unfavorable outcome (i.e., they were grouped with patients who did not have remission or who had a relapse). Analyses of the primary and key secondary end points were adjusted for age and number of treatment failures. RESULTS: Overall, 336 patients were assigned to the esketamine group and 340 to the quetiapine group. More patients in the esketamine group than in the quetiapine group had remission at week 8 (91 of 336 patients [27.1%] vs. 60 of 340 patients [17.6%]; P = 0.003) and had no relapse through week 32 after remission at week 8 (73 of 336 patients [21.7%] vs. 48 of 340 patients [14.1%]). Over 32 weeks of follow-up, the percentage of patients with remission, the percentage of patients with a treatment response, and the change in the MADRS score from baseline favored esketamine nasal spray. The adverse events were consistent with the established safety profiles of the trial treatments. CONCLUSIONS: In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8. (Funded by Janssen EMEA; ESCAPE-TRD ClinicalTrials.gov number, NCT04338321.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ESCAPE-TRD trial reported a comparatively smaller effect size for esketamine versus quetiapine (− 2.2 MADRS points; 95% CI, − 3.6 to − 0.8) at 32 weeks [19].”
In the citing paper
“At 8 weeks, esketamine nasal spray demonstrated superior efficacy [19].”
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Self-citationDaly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Cited by
Items 201–218 of 218
Ather, N., Zahid, M., Hassan, M., Zahid, M., Abbas, N., Rasheed, T., Ahsun, H., Khan, M. S., & Khan, M. M. (2026) · Annals of Clinical Psychiatry · doi:10.1177/10401237261473589
Last resort: the ethical obligation to offer ketamine in psychiatric euthanasia and assisted suicide
Zhang, J., & Sisti, D. A. (2026) · Journal of Medical Ethics · doi:10.1136/jme-2025-111672
Xu, T., Zhang, C., Yang, Y., Shen, Z., & Zhong, Z. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0340
Gründer, G. (2026) · Elsevier eBooks · doi:10.1016/b978-3-437-21293-2.00009-5
Der Weg zum Medikament: Arzneimittelprüfung, Zulassung, Nutzenbewertung
Gründer, G., & Mertens, L. J. (2026) · Elsevier eBooks · doi:10.1016/b978-3-437-21293-2.00023-x
Shared Decision-Making Music Therapy With Esketamine for Treatment-Resistant Depression
Herb, T., Lee, H., Mullick, P. K., & Palmer, J. E. (2026) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2026.105951
Varela, Y. M., Cavalcanti-Ribeiro, P., de Sousa, G. M., Falchi-Carvalho, M., Barbalho, J. D. S. F., Gomes, R. B. D. O., Gurgel, M. M. M., Pereira, B. C., Souza, P. M. D. L., Gonçalves, K. T. D. C., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.122369 · Cited by 1
Vestring, S., Domschke, K., & Normann, C. (2026) · Der Nervenarzt · doi:10.1007/s00115-026-02001-1
Kallarackal, J., Dyer, B. J., & Huang, J. (2026) · Springer eBooks · doi:10.1007/978-3-032-25214-2_36
Ali, M. A. S., Amirthalingam, P., Alshareef, H. M., Alassiry, M. Z., Elshenawy, A. S., Mansour, S. H. E.-D., & Aljabri, A. M. (2026) · Healthcare · doi:10.3390/healthcare14172717
McIntyre, R. S. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2726227
Evaluating seltorexant as a treatment option for major depressive disorder
Nicola, M. D., Pepe, M., Marcelli, I., Panaccione, I., & Sani, G. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2717199
“…superiority over quetiapine extended release in a head-to-head trial, with both compounds administered in combination with ongoing treatment with SSRIs/SNRIs [46]; of note, esketamine has also been approved by the US Food and Drug Administration as a monotherapy in early 2025 for TRD [47,48].”
Llorca, P., Sauvaget, A., Olié, É., Mékaoui, L., Samalin, L., Rothärmel, M., Boitez, A.-L., Dupin, J., Wicart, C., Gaudre-Wattinne, E., et al. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253261463652 · Cited by 1
“16 The higher remission and response rates were also demonstrated against quetiapine in TRD patients 17 and corroborated by a recent meta-analysis.”
Self-citationTargeting depression: Pharmacological mechanisms and therapeutic targets
Wang, H., Dong, S., Liu, S., Lai, K., & Chen, N. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109121
Ren, Y., Li, Y.-T., Yin, Q.-L., Li, H.-P., Zhang, P.-J., Cao, J.-H., Yu, B., Yang, X.-L., Yang, Z.-Z., & Kong, H. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2732292
“PP analysis confirmed these results (116 [10] vs. 107 [12]; mean difference 9 [95% CI 5 to 12]; p < 0.001; Table 2, Figure 2(D)).”
InfluentialWu, L., Cheng, W., Xiang, H., Zhu, Y., Jiang, Y., Wei, Z., Shao, M., Tian, L., Sun, Y., & Lu, C. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122427
Kinney, M. M., & Bowers, Z. L. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1949261
Psychopharmakotherapie – klinisch-empirische Grundlagen
Kasper, S. F., Hasan, A., & Möller, H. (2026) · Springer Reference Medizin · doi:10.1007/978-3-642-45028-0_31-2
Metadata
- Authors
- Reif, A., Bitter, I., Buyze, J., Cebulla, K., Frey, R., Fu, D.-J., Ito, T., Kambarov, Y., Llorca, P.-M., Oliveira-Maia, A. J., Messer, T., Mulhern-Haughey, S., Rive, B., von Holt, C., Young, A. H., & Godinov, Y.
- Affiliations
- Semmelweis University (HU)
- From the Department of Psychiatry, Psychosomatic Medicine, and Psychotherapy, University Hospital, Goethe University Frankfurt, and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt (A.R.), Danuvius Klinik, Technische Universität München, Pfaffenhofen an der Ilm (T.M.), and Janssen Germany (K.C.) and Janssen EMEA (C.H.), Neuss — all in Germany; the Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary (I.B.); Janssen Pharmaceutica (J.B.) and Janssen EMEA (Y.K.) — both in Beerse, Belgium; the Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna (R.F.); Janssen Research and Development, New Jersey (D.-J.F.); Janssen EMEA, High Wycombe (T.I.), the Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, and South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Beckenham (A.H.Y.) — all in the United Kingdom; CHU Clermont-Ferrand, Departme...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-10-05
- Volume
- 389
- Issue
- 14
- Pages
- 1298-1309
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4387324672
- Cited by
- 222
- References
- 29
- Citations by year
- 2026: 76 · 2025: 80 · 2024: 58 · 2023: 8
- FWCI
- 34.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Janssen EMEA
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- esketamine, quetiapine, treatment-resistant depression, augmentation therapy, remission, relapse prevention, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antidepressant efficacy, adverse events, NMDA receptor antagonists, ketamine, atypical antipsychotics, Montgomery-Asberg Depression Rating Scale, treatment response
- MeSH terms
- Serotonin and Noradrenaline Reuptake Inhibitors, Quetiapine Fumarate, Antidepressive Agents, Delayed-Action Preparations, Depression, Drug Therapy, Combination, Humans, Ketamine, Recurrence, Single-Blind Method, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Nasal Sprays, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.